ClinicalTrials.gg
TerminatedNCT05327803Updated Jun 10, 2026Results posted

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

A Phase 2/3 interventional study of Epetraborole and Placebo in MAC Lung Disease and Treatment Refractory MAC Lung Disease, sponsored by AN2 Therapeutics, Inc. Terminated at 91 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by AN2 Therapeutics, Inc · Phase 2/3, Interventional, and Treatment

Why this study was terminated
EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 210 studies in Respiratory Tract Infections with a site in United States — 21 open to participants now, 28 under way, 5 of them phase 3. Respiratory Tract Infections · United States.

Enrollment
72nd of 160
177 · median 137
Started
2022
with 10 others
Phase 2/3
2 of 210
none open now
Registered
163rd of 210
by date

Among the 210 studies in Respiratory Tract Infections with a site in United States, this one is the 72nd largest by enrollment of the 160 interventional ones that give a count, is one of 11 that started in 2022, is one of 2 in phase 2/3, and was the 163rd registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

21 of the 210 studies in Respiratory Tract Infections with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Respiratory Tract Infections with a site in United States, or all of them as a file.
02

Study summary

This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. This study will enroll adult patients with treatment-refractory MAC lung disease who meet all eligibility criteria (including clinical, radiographic, and microbiological criteria).

Read the detailed description

In the Phase 2 part of the study, approximately 80 patients will be randomized in a 1:1 ratio (40 patients receiving active epetraborole tablets and 40 patients receiving matching placebo tablets). The Phase 2 part of the study includes a blinded psychometric analysis plan to assess the psychometric properties of a novel PRO instrument. In addition, symptom-based clinical responses will be assessed using blinded data, to inform the measurement of clinical response in the Phase 3 part of the study.

The Phase 3 part of the study will test the superiority of epetraborole + OBR compared to placebo + OBR. In this part of the study, approximately 234 patients are planned to be randomized in a 2:1 ratio (156 patients receiving active epetraborole tablets and 78 patients receiving matching placebo tablets). The current symptom-based clinical response definition (using the novel PRO) in Phase 3 is a placeholder to be verified after Phase 2 analyses based on data through Month 6. In addition, the Sponsor will determine if the sample size for Phase 3 should be adjusted and will verify the Phase 3 epetraborole dosage regimen based on the observed plasma epetraborole exposure.

Phase 3 data analyses will include a review of patient-reported outcomes, microbiological, safety, and PK data collected at multiple time points through Month 6. Patients in Phase 3 will continue double-blinded study drug for 12 months after the first negative MAC culture that defines sputum culture conversion; study drug will be discontinued in patients who remain MAC culture positive despite 6 months of therapy with study drug.

03

Conditions studied

  • MAC Lung Disease
  • Treatment Refractory MAC Lung Disease

Keywords

  • NTM
  • Respiratory Infection
  • antimycobacterial activity
  • antimycobacterial agent
  • antimycobacterial therapy
  • MAC infections
  • MAC lung disease
  • MAC lung infection
  • MAC pulmonary infection
  • Mycobacteria
  • mycobacterial disease
  • mycobacterium
  • Mycobacterium Avium Complex
  • Mycobacterium Avium Complex Infections
  • Mycobacterium avium complex lung disease
  • Mycobacterium Infections
  • Nontuberculous
  • Nontuberculous mycobacteria / mycobacterial / mycobacterium
  • Non-tuberculous mycobacteria disease
  • Non-tuberculous mycobacterial (NTM) infections
  • Nontuberculous mycobacterial lung disease
  • Non-tuberculous mycobacterial lung disease
  • Nontuberculous mycobacterial pulmonary disease
  • NTM infection
  • NTM lung disease
  • NTM Pulmonary Disease
  • NTM lung infection
  • Pulmonary MAC disease
  • Pulmonary MAC lung disease
  • Pulmonary Mycobacterium Avium Complex disease
  • Treatment refractory MAC lung disease
  • Treatment refractory mycobacterial lung disease
  • Treatment refractory NTM lung disease
  • Treatment refractory NTM lung infection
  • Treatment refractory NTM pulmonary disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients who are 18 years of age or older.
  2. Willing and able to provide written .
  3. Patients with a diagnosis of treatment- MAC lung disease consisting of all of the following (a) Microbiological, (b) Clinical, and (c) Radiographic criteria:

    1. Microbiological criteria:

      • One Pre-Study MAC-positive respiratory specimen. Documentation of a MAC positive specimen collected per standard of care within 6 months prior to signing the informed consent form (ICF).
      • One Screening MAC-positive expectorated or induced sputum sample.
    2. Clinical criteria: At least 2 of the following patient-reported clinical symptoms:

      • Cough with sputum production
      • Cough without sputum
      • Chest congestion
      • Hemoptysis
      • Dyspnea
      • Fatigue
      • Night sweats or unusual sweating
    3. Radiographic criteria: Non contrast Chest CT scan within 6 months prior to signing the ICF with abnormalities consistent with MAC lung disease.
    4. OBR criteria: An OBR is a combination regimen that consists of ≥2 antimycobacterial agents. The patient-specific OBR must be administered for a minimum duration of 6 consecutive months that is either ongoing at the time of Screening or was stopped or paused no more than 12 months before screening. The OBR regimen administered during Screening must be continued after randomization.
  4. Patients who are willing to comply with all the study activities and procedures throughout the duration of the study and comply with all planned study visits and study procedures from Screening through the LFU Visit.
  5. All patients must agree to use an effective method of .
  6. Patients expected to survive with continued antimycobacterial therapy and appropriate supportive care from Screening through the LFU Visit, in the judgment of the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a presence of any suspected or confirmed disease or condition at Screening or the time of randomization that, in the opinion of the Investigator, may confound the assessment of symptom-based clinical response.
  2. Patients with active pulmonary or any malignancy that required or would require chemotherapy or radiation therapy within 1 year prior to randomization through the LFU Visit.
  3. Patients with (CrCl) of ≤30 mL/min, as estimated by the Cockcroft Gault formula, at Screening.
  4. Patients with \<10.0 g/dL or \<6.2 mmol/L at Screening; donation of blood or plasma within 28 days prior to randomization; or symptomatic loss of blood or hemorrhage within 28 days prior to randomization.
  5. Patients with severe hemoptysis within 28 days prior to randomization, defined as >100 mL over any 24-hour period or severe or extremely severe hemoptysis.
  6. Patients with severe hepatic impairment, as evidenced by (ALT) or aspartate aminotransferase (AST) >3 × (ULN) or total >2 × ULN, or clinical signs of cirrhosis or end-stage hepatic disease.
  7. Patients who are pregnant or breastfeeding.
  8. Patients with a mean corrected using Fridericia's formula (QTcF) >480 msec based on triplicate 12-lead ECGs at Screening.
  9. Patients with an immunodeficiency or an condition and risk for an opportunistic pulmonary infection.
  10. Patients with an anticipated start of new non-study antimycobacterial therapy to be administered at any time between Screening and Month 6.
  11. Patients who have received any medication during the 30 days or 5 half-lives, whichever is longer, prior to randomization.
  12. Patients with any prior exposure to epetraborole.
  13. Patients with any condition that, in the opinion of the Investigator, interferes with the ability to safely complete the study or adhere to study requirements, including the patient's inability or unwillingness to comply with all study assessments and visits.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
177 participants (actual)

Study arms

  • Experimental
    epetraborole + OBR

    epetraborole + Optimized Background Regimen

    Drug: Epetraborole

  • Placebo comparator
    placebo + OBR

    Placebo + Optimized Background Regimen

    Drug: Placebo

Interventions

  • 500 mg taken orally QD

    Also known as: AN2-501971

  • DrugPlacebo

    Placebo taken orally QD

06

What researchers measure

Primary outcomes

  1. Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole

    Percentage of Participants reporting treatment emergent adverse events

    Time frame: Baseline to Month 16

  2. Phase 2: Percentage of Participants Achieving Clinical Response

    Detection of within-patient changes in symptoms reported in a novel Patient-Reported Outcome (PRO) instrument at Month 6 (Clinical Response measured as improvement in at least one symptom and no worsening in any others from baseline)

    Time frame: Baseline to Month 6

  3. Phase 3: Percentage of Participants Achieving Clinical Response

    Detection of within-patient changes in symptoms reported in a novel Patient-Reported Outcome (PRO) instrument at Month 6 (Clinical Response measured as improvement in at least one symptom and no worsening in any others from baseline)

    Time frame: Baseline to Month 6

Secondary outcomes

  1. Phase 2: Percentage of Participants Achieving Culture Conversion

    Sputum conversion will be assessed using culture conversion based on 3 consecutive monthly negative sputum cultures for MAC by Month 6.

    Time frame: Baseline to Month 6

  2. Phase 2: Percentage of Participants Achieving Microbiological Improvement

    Microbiological improvement will be assessed at Month 3 and Month 6 using decrease in MAC colony counts of ≥1 category.

    Time frame: Baseline to Month 6

  3. Phase 2: Change From Baseline in QOL-B Respiratory Domain PRO

    Mean change from baseline in Quality of Life - Bronchiectasis (QOL-B) respiratory domain score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). QOL-B respiratory domain score is measured on a scale from 0 to 100 (with higher scores indicating better health-related quality of life).

    Time frame: Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported

  4. Phase 2: Change From Baseline in NTM Symptoms Module PRO

    Mean change from baseline in NTM Symptoms Module PRO measured monthly through Month 6 (Change from Baseline to Month 6 Reported). NTM Symptoms Module score is measured on a scale from 0 to 100 (with higher scores indicating better function).

    Time frame: Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported

  5. Phase 2: Change From Baseline in SGRQ-C PRO

    Mean change from baseline in Saint George's Respiratory Questionnaire for COPD Patients (SGRQ-C) total score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). SGRQ-C total score is measured on a scale from 0 to 100 (with lower scores representing better quality of life).

    Time frame: Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported

  6. Phase 2: Concordance Analysis of PRO-based Clinical Response and Microbiological Response

    Concordance between clinical response in a novel Patient-Reported Outcome (PRO) instrument and microbiological response will be assessed at Months 3 and 6. Microbiological response will be assessed using both sputum culture conversion and microbiological improvement.

    Time frame: Baseline to Month 6

  7. Phase 2: Maximum Plasma Concentration (Cmax) of Epetraborole

    Cmax is the maximum plasma concentration of epetraborole estimated by population PK model.

    Time frame: Day 1 (2-3 hours post-dose) and Day 29 (within 1 hour pre-dose and 2-3 hours post-dose); Day 29 Result Reported

  8. Phase 2: Area Under the Plasma Concentration-Time Curve From Time Point 0 Hours Until 24 Hours [AUC(0-24)] Post Dose

    AUC(0-24) is defined as area under the plasma concentration-time curve of epetraborole from timepoint 0 hours until 24 hours post dose estimated by population PK model.

    Time frame: Day 1 (2-3 hours post-dose) and Day 29 (within 1 hour pre-dose and 2-3 hours post-dose); Day 1 Result Reported

  9. Phase 2: Volume of Distribution (Vd) of Epetraborole

    Vd is the apparent volume of distribution of epetraborole estimated by population PK model.

    Time frame: Day 1 (2-3 hours post-dose) and Day 29 (within 1 hour pre-dose and 2-3 hours post-dose); Day 29 Result Reported

  10. Phase 3: Percentage of Participants Achieving Culture Conversion

    Sputum conversion will be assessed using culture conversion based on 3 consecutive monthly negative sputum cultures for MAC by Month 6.

    Time frame: Baseline to Month 6

  11. Phase 3: Percentage of Participants Achieving Microbiological Improvement

    Microbiological improvement will be assessed at Month 3 and Month 6 using decrease in MAC colony counts of ≥1 category.

    Time frame: Baseline to Month 6

  12. Phase 3: Change From Baseline in QOL-B Respiratory Domain PRO

    Mean change from baseline in Quality of Life - Bronchiectasis (QOL-B) respiratory domain score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). QOL-B respiratory domain score is measured on a scale from 0 to 100 (with higher scores indicating better health-related quality of life).

    Time frame: Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported

  13. Phase 3: Change From Baseline in NTM Symptoms Module PRO

    Mean change from baseline in NTM Symptoms Module PRO measured monthly through Month 6 (Change from Baseline to Month 6 Reported). NTM Symptoms Module score is measured on a scale from 0 to 100 (with higher scores indicating better function).

    Time frame: Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported

  14. Phase 3: Change From Baseline in SGRQ-C PRO

    Mean change from baseline in Saint George's Respiratory Questionnaire for COPD Patients (SGRQ-C) total score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). SGRQ-C total score is measured on a scale from 0 to 100 (with lower scores representing better quality of life).

    Time frame: Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported

  15. Phase 3: Concordance Analysis of PRO-based Clinical Response and Microbiological Response

    Concordance between clinical response in a novel Patient-Reported Outcome (PRO) instrument and microbiological response will be assessed at Months 3 and 6. Microbiological response will be assessed using both sputum culture conversion and microbiological improvement

    Time frame: Baseline to Month 6

  16. Phase 3: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole

    Percentage of Participants reporting treatment emergent adverse events.

    Time frame: Baseline to Month 16

07

Results

Posted Jun 10, 2026

Participant flow

This study included 2 phases of enrollment. 80 participants in Phase 2 were randomized 1:1 to Epetraborole or Placebo arms, both including Optimized Background Regimen (OBR) 97 participants in Phase 3 were randomized 2:1 to Epetraborole or Placebo arms, both including Optimized Background Regimen (OBR)

Phase 2
Participant flow — Phase 2
MilestoneEpetraborole + OBRPlacebo + OBR
Started3941
Completed3534
Not completed47
Phase 3
Participant flow — Phase 3
MilestoneEpetraborole + OBRPlacebo + OBR
Started6631
Completed5222
Not completed149

Outcome measures

PrimaryPhase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole

Percentage of Participants reporting treatment emergent adverse events

Time frame:
Baseline to Month 16
Reported as:
Count of participants · Participants
Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole
ParticipantsEpetraborole + OBRPlacebo + OBR
Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole3735
PrimaryPhase 2: Percentage of Participants Achieving Clinical Response

Detection of within-patient changes in symptoms reported in a novel Patient-Reported Outcome (PRO) instrument at Month 6 (Clinical Response measured as improvement in at least one symptom and no worsening in any others from baseline)

Time frame:
Baseline to Month 6
Reported as:
Count of participants · Participants
Phase 2: Percentage of Participants Achieving Clinical Response
ParticipantsEpetraborole + OBRPlacebo + OBR
Phase 2: Percentage of Participants Achieving Clinical Response1510
Statistical analysis
  • Epetraborole + OBR vs Placebo + OBR · Miettinen and Nurminen Test · p = 0.1863 · Risk difference (rd): 13.9 · 95% CI -6.8 to 33.8
SecondaryPhase 2: Percentage of Participants Achieving Culture Conversion

Sputum conversion will be assessed using culture conversion based on 3 consecutive monthly negative sputum cultures for MAC by Month 6.

Time frame:
Baseline to Month 6
Reported as:
Count of participants · Participants
Phase 2: Percentage of Participants Achieving Culture Conversion
ParticipantsEpetraborole + OBRPlacebo + OBR
Phase 2: Percentage of Participants Achieving Culture Conversion54
Statistical analysis
  • Epetraborole + OBR vs Placebo + OBR · Miettinen and Nurminen Test · p = 0.6366 · Risk difference (rd): 3.4 · 95% CI -12.0 to 19.8
SecondaryPhase 2: Percentage of Participants Achieving Microbiological Improvement

Microbiological improvement will be assessed at Month 3 and Month 6 using decrease in MAC colony counts of ≥1 category.

Time frame:
Baseline to Month 6
Reported as:
Count of participants · Participants
Phase 2: Percentage of Participants Achieving Microbiological Improvement
ParticipantsEpetraborole + OBRPlacebo + OBR
Phase 2: Percentage of Participants Achieving Microbiological Improvement916
Statistical analysis
  • Epetraborole + OBR vs Placebo + OBR · Miettinen and Nurminen Test · p = 0.1816 · Risk difference (rd): -14.7 · 95% CI -35.3 to 7.2
SecondaryPhase 2: Change From Baseline in QOL-B Respiratory Domain PRO

Mean change from baseline in Quality of Life - Bronchiectasis (QOL-B) respiratory domain score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). QOL-B respiratory domain score is measured on a scale from 0 to 100 (with higher scores indicating better health-related quality of life).

Time frame:
Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported
Reported as:
Least squares mean · Change from baseline score
Phase 2: Change From Baseline in QOL-B Respiratory Domain PRO
Change from baseline scoreEpetraborole + OBRPlacebo + OBR
Phase 2: Change From Baseline in QOL-B Respiratory Domain PRO7.20 ± 2.4470.30 ± 2.569
Statistical analysis
  • Epetraborole + OBR vs Placebo + OBR · ANCOVA · p = 0.0365 · Mean difference (final values): 6.90 · 95% CI 0.45 to 13.36
SecondaryPhase 2: Change From Baseline in NTM Symptoms Module PRO

Mean change from baseline in NTM Symptoms Module PRO measured monthly through Month 6 (Change from Baseline to Month 6 Reported). NTM Symptoms Module score is measured on a scale from 0 to 100 (with higher scores indicating better function).

Time frame:
Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported
Reported as:
Least squares mean · Change from baseline score
Phase 2: Change From Baseline in NTM Symptoms Module PRO
Change from baseline scoreEpetraborole + OBRPlacebo + OBR
Phase 2: Change From Baseline in NTM Symptoms Module PRO6.20 ± 2.5990.83 ± 2.746
Statistical analysis
  • Epetraborole + OBR vs Placebo + OBR · ANCOVA · p = 0.1213 · Mean difference (final values): 5.37 · 95% CI -1.46 to 12.20
SecondaryPhase 2: Change From Baseline in SGRQ-C PRO

Mean change from baseline in Saint George's Respiratory Questionnaire for COPD Patients (SGRQ-C) total score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). SGRQ-C total score is measured on a scale from 0 to 100 (with lower scores representing better quality of life).

Time frame:
Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported
Reported as:
Least squares mean · Change from baseline score
Phase 2: Change From Baseline in SGRQ-C PRO
Change from baseline scoreEpetraborole + OBRPlacebo + OBR
Phase 2: Change From Baseline in SGRQ-C PRO-2.27 ± 2.3170.33 ± 2.464
Statistical analysis
  • Epetraborole + OBR vs Placebo + OBR · ANCOVA · p = 0.4048 · Mean difference (final values): -2.60 · 95% CI -8.80 to 3.60
SecondaryPhase 2: Concordance Analysis of PRO-based Clinical Response and Microbiological Response

Concordance between clinical response in a novel Patient-Reported Outcome (PRO) instrument and microbiological response will be assessed at Months 3 and 6. Microbiological response will be assessed using both sputum culture conversion and microbiological improvement.

Time frame:
Baseline to Month 6
Reported as:
Count of participants · Participants
Phase 2: Concordance Analysis of PRO-based Clinical Response and Microbiological Response
ParticipantsEpetraborole + OBRPlacebo + OBR
PRO responder and culture conversion21
PRO responder and no culture conversion139
PRO failure and culture conversion33
PRO failure and no culture conversion2027
SecondaryPhase 2: Maximum Plasma Concentration (Cmax) of Epetraborole

Cmax is the maximum plasma concentration of epetraborole estimated by population PK model.

Time frame:
Day 1 (2-3 hours post-dose) and Day 29 (within 1 hour pre-dose and 2-3 hours post-dose); Day 29 Result Reported
Reported as:
Geometric mean · ug/mL
Phase 2: Maximum Plasma Concentration (Cmax) of Epetraborole
ug/mLEpetraborole + OBRPlacebo + OBR
Phase 2: Maximum Plasma Concentration (Cmax) of Epetraborole2.73 ± 18.9—
SecondaryPhase 2: Area Under the Plasma Concentration-Time Curve From Time Point 0 Hours Until 24 Hours [AUC(0-24)] Post Dose

AUC(0-24) is defined as area under the plasma concentration-time curve of epetraborole from timepoint 0 hours until 24 hours post dose estimated by population PK model.

Time frame:
Day 1 (2-3 hours post-dose) and Day 29 (within 1 hour pre-dose and 2-3 hours post-dose); Day 1 Result Reported
Reported as:
Geometric mean · ug*hr/mL
Phase 2: Area Under the Plasma Concentration-Time Curve From Time Point 0 Hours Until 24 Hours [AUC(0-24)] Post Dose
ug*hr/mLEpetraborole + OBRPlacebo + OBR
Phase 2: Area Under the Plasma Concentration-Time Curve From Time Point 0 Hours Until 24 Hours [AUC(0-24)] Post Dose14.8 ± 19.8—
SecondaryPhase 2: Volume of Distribution (Vd) of Epetraborole

Vd is the apparent volume of distribution of epetraborole estimated by population PK model.

Time frame:
Day 1 (2-3 hours post-dose) and Day 29 (within 1 hour pre-dose and 2-3 hours post-dose); Day 29 Result Reported
Reported as:
Geometric mean · L
Phase 2: Volume of Distribution (Vd) of Epetraborole
LEpetraborole + OBRPlacebo + OBR
Phase 2: Volume of Distribution (Vd) of Epetraborole174 ± 16.2—
SecondaryPhase 3: Percentage of Participants Achieving Culture Conversion

Sputum conversion will be assessed using culture conversion based on 3 consecutive monthly negative sputum cultures for MAC by Month 6.

Time frame:
Baseline to Month 6
Reported as:
Count of participants · Participants
Phase 3: Percentage of Participants Achieving Culture Conversion
ParticipantsEpetraborole + OBRPlacebo + OBR
Phase 3: Percentage of Participants Achieving Culture Conversion53
Statistical analysis
  • Epetraborole + OBR vs Placebo + OBR · Miettinen and Nurminen Test · p = 0.7374 · Risk difference (rd): -2.0 · 95% CI -18.3 to 9.6
SecondaryPhase 3: Percentage of Participants Achieving Microbiological Improvement

Microbiological improvement will be assessed at Month 3 and Month 6 using decrease in MAC colony counts of ≥1 category.

Time frame:
Baseline to Month 6
Reported as:
Count of participants · Participants
Phase 3: Percentage of Participants Achieving Microbiological Improvement
ParticipantsEpetraborole + OBRPlacebo + OBR
Phase 3: Percentage of Participants Achieving Microbiological Improvement207
Statistical analysis
  • Epetraborole + OBR vs Placebo + OBR · Miettinen and Nurminen Test · p = 0.4770 · Risk difference (rd): 7.8 · 95% CI -14.4 to 26.5
SecondaryPhase 3: Change From Baseline in QOL-B Respiratory Domain PRO

Mean change from baseline in Quality of Life - Bronchiectasis (QOL-B) respiratory domain score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). QOL-B respiratory domain score is measured on a scale from 0 to 100 (with higher scores indicating better health-related quality of life).

Time frame:
Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported
Reported as:
Least squares mean · Change from baseline score
Phase 3: Change From Baseline in QOL-B Respiratory Domain PRO
Change from baseline scoreEpetraborole + OBRPlacebo + OBR
Phase 3: Change From Baseline in QOL-B Respiratory Domain PRO5.14 ± 2.2524.16 ± 2.748
Statistical analysis
  • Epetraborole + OBR vs Placebo + OBR · ANCOVA · p = 0.7551 · Mean difference (final values): 0.98 · 95% CI -5.28 to 7.25
SecondaryPhase 3: Change From Baseline in NTM Symptoms Module PRO

Mean change from baseline in NTM Symptoms Module PRO measured monthly through Month 6 (Change from Baseline to Month 6 Reported). NTM Symptoms Module score is measured on a scale from 0 to 100 (with higher scores indicating better function).

Time frame:
Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported
Reported as:
Least squares mean · Change from baseline score
Phase 3: Change From Baseline in NTM Symptoms Module PRO
Change from baseline scoreEpetraborole + OBRPlacebo + OBR
Phase 3: Change From Baseline in NTM Symptoms Module PRO3.55 ± 2.4771.66 ± 3.032
Statistical analysis
  • Epetraborole + OBR vs Placebo + OBR · ANCOVA · p = 0.5854 · Mean difference (final values): 1.88 · 95% CI -4.96 to 8.72
SecondaryPhase 3: Change From Baseline in SGRQ-C PRO

Mean change from baseline in Saint George's Respiratory Questionnaire for COPD Patients (SGRQ-C) total score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). SGRQ-C total score is measured on a scale from 0 to 100 (with lower scores representing better quality of life).

Time frame:
Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported
Reported as:
Least squares mean · Change from baseline total score
Phase 3: Change From Baseline in SGRQ-C PRO
Change from baseline total scoreEpetraborole + OBRPlacebo + OBR
Phase 3: Change From Baseline in SGRQ-C PRO-2.49 ± 1.873-3.36 ± 2.308
Statistical analysis
  • Epetraborole + OBR vs Placebo + OBR · ANCOVA · p = 0.7403 · Mean difference (final values): 0.87 · 95% CI -4.35 to 6.09
SecondaryPhase 3: Concordance Analysis of PRO-based Clinical Response and Microbiological Response

Concordance between clinical response in a novel Patient-Reported Outcome (PRO) instrument and microbiological response will be assessed at Months 3 and 6. Microbiological response will be assessed using both sputum culture conversion and microbiological improvement

Time frame:
Baseline to Month 6
Reported as:
Count of participants · Participants
Phase 3: Concordance Analysis of PRO-based Clinical Response and Microbiological Response
ParticipantsEpetraborole + OBRPlacebo + OBR
Clinical Response and Culture Conversion11
Clinical Response and No Culture Conversion209
Clinical Failure and Culture Conversion42
Clinical Failure and No Culture Conversion4019
SecondaryPhase 3: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole

Percentage of Participants reporting treatment emergent adverse events.

Time frame:
Baseline to Month 16
Reported as:
Count of participants · Participants
Phase 3: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole
ParticipantsEpetraborole + OBRPlacebo + OBR
Phase 3: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole5923
PrimaryPhase 3: Percentage of Participants Achieving Clinical Response

Detection of within-patient changes in symptoms reported in a novel Patient-Reported Outcome (PRO) instrument at Month 6 (Clinical Response measured as improvement in at least one symptom and no worsening in any others from baseline)

Time frame:
Baseline to Month 6
Reported as:
Count of participants · Participants
Phase 3: Percentage of Participants Achieving Clinical Response
ParticipantsEpetraborole + OBRPlacebo + OBR
Phase 3: Percentage of Participants Achieving Clinical Response2110
Statistical analysis
  • Epetraborole + OBR vs Placebo + OBR · Miettinen and Nurminen Test · p = 0.9822 · Risk difference (rd): -0.2 · 95% CI -20.8 to 18.6

Adverse events

Collected over Baseline to Month 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epetraborole + OBR4/105 (3.8%)15/105 (14.3%)67/105 (63.8%)
Placebo + OBR0/72 (0%)13/72 (18.1%)31/72 (43.1%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventEpetraborole + OBRPlacebo + OBR
Atypical mycobacterial infectionInfections and infestations3/1053/72
PneumoniaInfections and infestations1/1053/72
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/1050/72
Infective exacerbation of bronchiectasisInfections and infestations2/1050/72
Aortic stenosisVascular disorders0/1051/72
AsthmaRespiratory, thoracic and mediastinal disorders0/1051/72
DehydrationMetabolism and nutrition disorders0/1051/72
Device breakageProduct Issues0/1051/72
HaemoptysisRespiratory, thoracic and mediastinal disorders1/1051/72
PneumothoraxRespiratory, thoracic and mediastinal disorders1/1051/72
Most frequent other events
Most frequent other events
EventEpetraborole + OBRPlacebo + OBR
AnaemiaBlood and lymphatic system disorders30/1051/72
HeadacheNervous system disorders10/10511/72
Haemoglobin decreasedInvestigations12/1050/72
NasopharyngitisInfections and infestations7/1058/72
DizzinessNervous system disorders11/1051/72
COVID -19Infections and infestations9/1057/72
NauseaGastrointestinal disorders10/1053/72
DiarrhoeaGastrointestinal disorders6/1053/72

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase 2 : Epetraborole + OBRPhase 2 : Placebo + OBRPhase 3 : Epetraborole + OBRPhase 3 : Placebo + OBRTotal
<=18 years00000
Between 18 and 65 years1818211370
>=65 years21234518107
Sex: Female, Male
Sex: Female, Male(Participants)Phase 2 : Epetraborole + OBRPhase 2 : Placebo + OBRPhase 3 : Epetraborole + OBRPhase 3 : Placebo + OBRTotal
Female27304922128
Male121117949
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 2 : Epetraborole + OBRPhase 2 : Placebo + OBRPhase 3 : Epetraborole + OBRPhase 3 : Placebo + OBRTotal
American Indian or Alaska Native00000
Asian26253923113
Native Hawaiian or Other Pacific Islander00000
Black or African American01203
White131523859
More than one race00202
Unknown or Not Reported00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 2 : Epetraborole + OBRPhase 2 : Placebo + OBRPhase 3 : Epetraborole + OBRPhase 3 : Placebo + OBRTotal
Hispanic or Latino10214
Not Hispanic or Latino38416430173
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Phase 2 : Epetraborole + OBRPhase 2 : Placebo + OBRPhase 3 : Epetraborole + OBRPhase 3 : Placebo + OBRTotal
United States111526759
Australia21216
Japan1814311780
South Korea8117632
08

Study locations

91 sites
  • 423032
    Birmingham, Alabama 35233, United States
  • 423037
    Tucson, Arizona 85724, United States
  • 423070
    Sacramento, California 95817, United States
  • 423069
    San Francisco, California 94143, United States
  • 423006
    Stanford, California 94305, United States
  • 423068
    Washington D.C., District of Columbia 20037, United States
  • 423075
    Bay Pines, Florida 33744, United States
  • 423018
    DeLand, Florida 32720, United States
  • 423034
    Kissimmee, Florida 34746, United States
  • 423033
    Tampa, Florida 33606, United States
  • 423054
    Tampa, Florida 33612, United States
  • 423047
    Tampa, Florida 33614, United States
  • 423038
    Vero Beach, Florida 32960, United States
  • 423027
    Atlanta, Georgia 30342, United States
  • 423076
    Indianapolis, Indiana 46202, United States
  • 423029
    Iowa City, Iowa 52242, United States
  • 423015
    Kansas City, Kansas 66205, United States
  • 423063
    Wichita, Kansas 67211, United States
  • 423065
    Jefferson, Louisiana 70121, United States
  • 423042
    New Orleans, Louisiana 70112, United States
  • 423060
    Baltimore, Maryland 21201, United States
  • 423003
    Baltimore, Maryland 21231, United States
  • 423074
    Boston, Massachusetts 02114-2696, United States
  • 423061
    Boston, Massachusetts 02115, United States
  • 423078
    Ann Arbor, Michigan 48109, United States
  • 423031
    Rochester, Minnesota 55902, United States
  • 423008
    St Louis, Missouri 63110, United States
  • 423004
    Omaha, Nebraska 68198, United States
  • 423009
    Lebanon, New Hampshire 03756, United States
  • 423024
    Manhasset, New York 11030, United States
  • 423014
    New York, New York 10017, United States
  • 423013
    New York, New York 10029, United States
  • 423071
    Chapel Hill, North Carolina 27599, United States
  • 423072
    Charlotte, North Carolina 28204, United States
  • 423017
    Durham, North Carolina 27705, United States
  • 423039
    Winston-Salem, North Carolina 27103, United States
  • 423079
    Cleveland, Ohio 44195, United States
  • 423082
    Oklahoma City, Oklahoma 73104, United States
  • 423007
    Portland, Oregon 97239, United States
  • 423002
    Philadelphia, Pennsylvania 19104, United States
  • 423058
    Philadelphia, Pennsylvania 19107, United States
  • 423045
    Charleston, South Carolina 29414, United States
  • 423001
    Charleston, South Carolina 29425, United States
  • 423067
    Nashville, Tennessee 37232, United States
  • 423081
    Fort Worth, Texas 76104, United States
  • 423005
    Tyler, Texas 75708, United States
  • 423012
    Charlottesville, Virginia 22908, United States
  • 423080
    Edmonds, Washington 98026, United States
  • 423011
    Milwaukee, Wisconsin 53226, United States
  • 501005
    Concord, New South Wales 2139, Australia
  • 501007
    Birtinya, Queensland 4575, Australia
  • 501003
    Chermside West, Queensland 4032, Australia
  • 501001
    Greenslopes, Queensland, Australia
  • 501008
    Perth, Western Australia 6000, Australia
  • 501004
    Clayton, 3168, Australia
  • 501002
    South Brisbane, 4101, Australia
  • 215019
    Aichi, 465-8620, Japan
  • 215026
    Aomori, 036-8563, Japan
  • 215004
    Fukuoka, 811-3195, Japan
  • 215025
    Fukuoka, 814-0180, Japan
  • 215016
    Fukuoka, 819-8555, Japan
  • 215006
    Gifu, 502-8558, Japan
  • 215030
    Hiroshima, 730-0822, Japan
  • 215014
    Hokkaido, 070-8644, Japan
  • 215028
    Ibaraki, 319-1113, Japan
  • 215018
    Ishikawa, 920-8530, Japan
  • 215020
    Ishikawa, 920-8650, Japan
  • 215017
    Kanagawa, 236-0051, Japan
  • 215021
    Kitakyushu, 806-0034, Japan
  • 215009
    Kyoto, 610-0113, Japan
  • 215013
    Kyoto, 612-8555, Japan
  • 215022
    Mie, 514-1101, Japan
  • 215023
    Nagano, 382-8577, Japan
  • 215002
    Niigata, 951-8510, Japan
  • 215029
    Osaka, 560-8552, Japan
  • 215008
    Osaka, 591-8555, Japan
  • 215012
    Osaka, 591-8555, Japan
  • 215001
    Tokyo, 160-8582, Japan
  • 215005
    Tokyo, 162-8655, Japan
  • 215024
    Tokyo, 180-8610, Japan
  • 215003
    Tokyo, 204-8522, Japan
  • 215027
    Tokyo, Japan
  • 215010
    Wakayama, 646-8558, Japan
  • 215007
    Yamaguchi, Japan
  • 215011
    Yokohama, 245-8575, Japan
  • 219003
    Gwangju, 61469, South Korea
  • 219005
    Incheon, 21431, South Korea
  • 219001
    Seongnam-si, 13620, South Korea
  • 219002
    Seoul, 03080, South Korea
  • 219007
    Seoul, 05505, South Korea
  • 219008
    Seoul, South Korea
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Dec 2024, 30 months.

Results were first posted in Jun 2026, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2022
First posted
Apr 14, 2022
StartActual
May 20, 2022
Primary completionActual
Dec 18, 2024
CompletionActual
Dec 18, 2024
Results first posted
Jun 10, 2026
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05327803
Lead sponsor
AN2 Therapeutics, Inc
Responsible party
Sponsor
First posted
Apr 14, 2022
Start date
May 20, 2022
Primary completion
Dec 18, 2024
Completion
Dec 18, 2024
Results posted
Jun 10, 2026
Last update
Jun 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epetraborole

Start the discussion